---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-262375"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-10-14T23:59:59+00:00"
generated_at: "2026-06-23T03:35:20.832045+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Imara and Enliven hold investor call on definitive merger; Enliven to become wholly owned subsidiary

## Summary
- Merger agreement provides for Enliven to survive as wholly owned subsidiary of Imara via a reverse merger.
- Joint investor conference call held on October 13, 2022 to discuss the transaction and its rationale.
- No deal value, premium, or expected close date disclosed in this filing or the appended transcript excerpt.

## SEC filing metadata
- accession: 0001193125-22-262375
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-10-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/0001193125-22-262375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312522262375/d397742d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-262375
- JSON: https://secwatch.observer/filing/0001193125-22-262375.json
- Plain text: https://secwatch.observer/filing/0001193125-22-262375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.